<p>Capital International Inc. CA 在第一季度减持强生（Johnson &amp; Johnson）股份，根据其最新向 SEC 提交的 13F 申报文件，持有公司股票 109,673 股，比期间减持 137,587 股，价值$17,349,000。</p>
<p>获取 <strong>强生（Johnson &amp; Johnson）</strong> 警报：</p>
<ul>
<li>直觉外科股表现优于市场：高点在望</li>
</ul>
<p>其他一些机构投资者最近也调整了对 JNJ 的持仓。Etesian Wealth Advisors Inc.在第四季度增持了 0.7% 的强生股份。现在持有公司股票 11,093 股，价值$1,737,000，比期间增持 73 股。Jessup Wealth Management Inc.在第四季度增持了 4.8% 的强生股份。现在持有公司股票 10,776 股，价值$1,689,000，比期间增持 491 股。Eclectic Associates Inc. ADV 在第四季度增持了 2.9% 的强生股份。现在持有公司股票 9,432 股，价值$1,478,000，比上一季度增持 270 股。Strategic Wealth Investment Group LLC 在第四季度增持了 18.0% 的强生股份。现在持有公司股票 34,989 股，价值$5,484,000，比期间增持 5,335 股。最后，Carlson Capital Management 在第四季度增持了 13.1% 的强生股份。现在持有公司股票 15,734 股，价值$2,466,000，比上一季度增持 1,822 股。对冲基金和其他机构投资者持有公司股份的比例为 69.55%。</p>
<h2>强生（Johnson &amp; Johnson）股价上涨 0.7%</h2>
<p>JNJ 股票周五在午盘交易中上涨$1.04，报价$160.68。公司股票交易量为 8,356,432 股，相比平均交易量 7,349,373 股有所增加。强生股票一年内最低价为$143.13，最高价为$175.97。公司的 50 天移动平均价格为$148.74，200 天移动平均价格为$153.24。公司的流动比率为 1.17，速动比率为 0.94，负债权益比为 0.36。股票市值为$386.71 十亿美元，市盈率为 10.02，市盈增长比为 2.56，贝塔系数为 0.52。</p>
<ul>
<li>MarketBeat 周评 - 7/15 - 7/19</li>
</ul>
<p>强生（Johnson &amp; Johnson）（NYSE:JNJ - 获取免费报告）上次公布季度财报是在 7 月 17 日星期三。公司报告该季度每股收益为$2.82，超过分析师预期的$2.71，超出$0.11。强生公司的净资产收益率为 36.79%，净利润率为 46.34%。该季度公司营收为 224.5 亿美元，超过分析师预期的 223.3 亿美元。去年同期，该公司每股收益为$2.80。公司营收同比增长 4.3%。卖方分析师预计，强生公司今年将实现每股盈利 10.07 美元。</p>
<h2>强生（Johnson &amp; Johnson）宣布股息</h2>
<p>公司最近宣布每季度支付股息，将于 9 月 10 日周二支付。股东记录日为 8 月 27 日周二，将支付每股$1.24 的股息。该股息的除息日为 8 月 27 日周二。这代表年化基础上的$4.96 股息和 3.09% 的收益率。强生公司的派息比率为 30.92%。</p>
<h2>分析师设定新的股价目标</h2>
<ul>
<li>这家医疗巨头股价反弹：最低涨幅 15%</li>
</ul>
<p>JNJ 最近受到多家分析师报告的关注。汇丰银行将强生股票评级从 “持有” 调高至 “买入”，并将目标股价从 169.00 美元提高至 170.00 美元。戴娃美国将强生股票评级从 “强买” 下调至 “持有”。卡恩特菲茨杰拉德重申对强生股票的 “超配” 评级，并设定了 215.00 美元的目标股价。加拿大皇家银行重申对强生股票的 “表现优异” 评级，并在 7 月 18 日星期四的研究报告中设定了 175.00 美元的目标股价。最后，摩根士丹利将强生股票的目标股价从 167.00 美元上调至 169.00 美元，并给予公司 “等权重” 评级。八家分析师对该股票给予持有评级，六家给予买入评级，一家给予强烈买入评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “中等买入”，平均目标股价为 173.00 美元。</p>
<p>阅读我们关于 JNJ 的最新研究报告</p>
<h2>强生（Johnson &amp; Johnson）公司简介（免费报告）</h2>
<p>强生及其子公司在全球范围内从事医疗保健领域的各种产品的研究、开发、制造和销售。该公司的创新药物部门提供各种治疗领域的产品，包括免疫学，如类风湿性关节炎、银屑病性关节炎、炎症性肠病和牛皮癣；传染病，包括艾滋病；神经科学，包括情绪障碍、神经退行性疾病和精神分裂症；肿瘤学，如前列腺癌、血液恶性肿瘤、肺癌和膀胱癌；心血管和代谢，包括血栓形成、糖尿病和黄斑变性；以及肺动脉高压，通过零售商、批发商、分销商、医院和医疗专业人士供处方使用。</p>
<h2>阅读更多</h2>
<ul>
<li>五只我们喜欢的股票，胜过强生</li>
<li>消费者价格指数衡量什么？</li>
<li>3M 惊喜和反弹加速：现在入场不算晚</li>
<li>复利利息如何计算？</li>
<li>斯凯奇股票在消费者自由选择行业表现强劲</li>
<li>什么是盈利惊喜？</li>
<li>科技股下跌，这些股票提供购买机会</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关本故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 下一个加密百万机会（来自 Crypto 101 Media）(广告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04Nzk0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04Nzk0"/></p>
<h2>现在是否值得投资$1,000 美元购买强生股票？</h2>
<p>在考虑购买强生股票之前，您需要听到这个消息。</p>
<p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户现在购买的股票，而强生股票不在名单上。</p>
<p>尽管强生目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

强生

<p>根据其最近向美国证券交易委员会提交的文件，Capital International Inc. CA 在第一季度期间将其持有的强生股份减少了 55.6%。该基金在此期间卖出了 137,587 股，持有公司股票的数量为 109,673 股</p>

<p>Capital International Inc. CA reduced its stake in Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 55.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 109,673 shares of the company's stock after selling 137,587 shares during the period. Capital International Inc. CA's holdings in Johnson &amp; Johnson were worth $17,349,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Capital International Inc. CA 在第一季度减持强生（Johnson &amp; Johnson）股份，根据其最新向 SEC 提交的 13F 申报文件，持有公司股票 109,673 股，比期间减持 137,587 股，价值$17,349,000。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<ul>
<li>Intuitive Surgical Stock Outperforms Market: Highs on the Horizon</li>
</ul>
<div class="lb-trans"><p>获取 <strong>强生（Johnson &amp; Johnson）</strong> 警报：</p>
<ul>
<li>直觉外科股表现优于市场：高点在望</li>
</ul>
</div><p>A number of other institutional investors have also recently made changes to their positions in JNJ. Etesian Wealth Advisors Inc. raised its holdings in Johnson &amp; Johnson by 0.7% during the 4th quarter. Etesian Wealth Advisors Inc. now owns 11,093 shares of the company's stock valued at $1,737,000 after buying an additional 73 shares during the period. Jessup Wealth Management Inc boosted its stake in shares of Johnson &amp; Johnson by 4.8% during the 4th quarter. Jessup Wealth Management Inc now owns 10,776 shares of the company's stock worth $1,689,000 after purchasing an additional 491 shares during the period. Eclectic Associates Inc. ADV grew its stake in shares of Johnson &amp; Johnson by 2.9% during the fourth quarter. Eclectic Associates Inc. ADV now owns 9,432 shares of the company's stock valued at $1,478,000 after buying an additional 270 shares during the last quarter. Strategic Wealth Investment Group LLC raised its holdings in shares of Johnson &amp; Johnson by 18.0% in the fourth quarter. Strategic Wealth Investment Group LLC now owns 34,989 shares of the company's stock worth $5,484,000 after buying an additional 5,335 shares during the period. Finally, Carlson Capital Management lifted its stake in shares of Johnson &amp; Johnson by 13.1% during the 4th quarter. Carlson Capital Management now owns 15,734 shares of the company's stock worth $2,466,000 after acquiring an additional 1,822 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.</p>
<div class="lb-trans"><p>其他一些机构投资者最近也调整了对 JNJ 的持仓。Etesian Wealth Advisors Inc.在第四季度增持了 0.7% 的强生股份。现在持有公司股票 11,093 股，价值$1,737,000，比期间增持 73 股。Jessup Wealth Management Inc.在第四季度增持了 4.8% 的强生股份。现在持有公司股票 10,776 股，价值$1,689,000，比期间增持 491 股。Eclectic Associates Inc. ADV 在第四季度增持了 2.9% 的强生股份。现在持有公司股票 9,432 股，价值$1,478,000，比上一季度增持 270 股。Strategic Wealth Investment Group LLC 在第四季度增持了 18.0% 的强生股份。现在持有公司股票 34,989 股，价值$5,484,000，比期间增持 5,335 股。最后，Carlson Capital Management 在第四季度增持了 13.1% 的强生股份。现在持有公司股票 15,734 股，价值$2,466,000，比上一季度增持 1,822 股。对冲基金和其他机构投资者持有公司股份的比例为 69.55%。</p>
</div><h2>Johnson &amp; Johnson Stock Up 0.7 %</h2>
<div class="lb-trans"><h2>强生（Johnson &amp; Johnson）股价上涨 0.7%</h2>
</div><p>Shares of JNJ traded up $1.04 during midday trading on Friday, hitting $160.68. 8,356,432 shares of the company's stock traded hands, compared to its average volume of 7,349,373. Johnson &amp; Johnson has a 1 year low of $143.13 and a 1 year high of $175.97. The firm's fifty day moving average is $148.74 and its 200-day moving average is $153.24. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $386.71 billion, a price-to-earnings ratio of 10.02, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52.</p>
<ul>
<li>MarketBeat Week in Review – 7/15 - 7/19</li>
</ul>
<div class="lb-trans"><p>JNJ 股票周五在午盘交易中上涨$1.04，报价$160.68。公司股票交易量为 8,356,432 股，相比平均交易量 7,349,373 股有所增加。强生股票一年内最低价为$143.13，最高价为$175.97。公司的 50 天移动平均价格为$148.74，200 天移动平均价格为$153.24。公司的流动比率为 1.17，速动比率为 0.94，负债权益比为 0.36。股票市值为$386.71 十亿美元，市盈率为 10.02，市盈增长比为 2.56，贝塔系数为 0.52。</p>
<ul>
<li>MarketBeat 周评 - 7/15 - 7/19</li>
</ul>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating analysts' consensus estimates of $2.71 by $0.11. Johnson &amp; Johnson had a return on equity of 36.79% and a net margin of 46.34%. The company had revenue of $22.45 billion during the quarter, compared to analysts' expectations of $22.33 billion. During the same period last year, the business posted $2.80 earnings per share. The firm's revenue was up 4.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Johnson &amp; Johnson will post 10.07 earnings per share for the current year.</p>
<div class="lb-trans"><p>强生（Johnson &amp; Johnson）（NYSE:JNJ - 获取免费报告）上次公布季度财报是在 7 月 17 日星期三。公司报告该季度每股收益为$2.82，超过分析师预期的$2.71，超出$0.11。强生公司的净资产收益率为 36.79%，净利润率为 46.34%。该季度公司营收为 224.5 亿美元，超过分析师预期的 223.3 亿美元。去年同期，该公司每股收益为$2.80。公司营收同比增长 4.3%。卖方分析师预计，强生公司今年将实现每股盈利 10.07 美元。</p>
</div><h2>Johnson &amp; Johnson Announces Dividend</h2>
<div class="lb-trans"><h2>强生（Johnson &amp; Johnson）宣布股息</h2>
</div><p>The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a yield of 3.09%. Johnson &amp; Johnson's payout ratio is 30.92%.</p>
<div class="lb-trans"><p>公司最近宣布每季度支付股息，将于 9 月 10 日周二支付。股东记录日为 8 月 27 日周二，将支付每股$1.24 的股息。该股息的除息日为 8 月 27 日周二。这代表年化基础上的$4.96 股息和 3.09% 的收益率。强生公司的派息比率为 30.92%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<ul>
<li>This Medical Giant's Stock Rebounds: A 15% Upside Is the Minimum</li>
</ul>
<div class="lb-trans"><h2>分析师设定新的股价目标</h2>
<ul>
<li>这家医疗巨头股价反弹：最低涨幅 15%</li>
</ul>
</div><p>JNJ has been the subject of a number of recent analyst reports. HSBC raised shares of Johnson &amp; Johnson from a &#34;hold&#34; rating to a &#34;buy&#34; rating and boosted their target price for the company from $169.00 to $170.00 in a research note on Thursday, April 18th. Daiwa America downgraded Johnson &amp; Johnson from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday. Cantor Fitzgerald restated an &#34;overweight&#34; rating and set a $215.00 price target on shares of Johnson &amp; Johnson in a research note on Monday, July 1st. Royal Bank of Canada reaffirmed an &#34;outperform&#34; rating and issued a $175.00 price objective on shares of Johnson &amp; Johnson in a research note on Thursday, July 18th. Finally, Morgan Stanley raised their target price on shares of Johnson &amp; Johnson from $167.00 to $169.00 and gave the company an &#34;equal weight&#34; rating in a research report on Thursday, July 18th. Eight analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $173.00.</p>
<div class="lb-trans"><p>JNJ 最近受到多家分析师报告的关注。汇丰银行将强生股票评级从 “持有” 调高至 “买入”，并将目标股价从 169.00 美元提高至 170.00 美元。戴娃美国将强生股票评级从 “强买” 下调至 “持有”。卡恩特菲茨杰拉德重申对强生股票的 “超配” 评级，并设定了 215.00 美元的目标股价。加拿大皇家银行重申对强生股票的 “表现优异” 评级，并在 7 月 18 日星期四的研究报告中设定了 175.00 美元的目标股价。最后，摩根士丹利将强生股票的目标股价从 167.00 美元上调至 169.00 美元，并给予公司 “等权重” 评级。八家分析师对该股票给予持有评级，六家给予买入评级，一家给予强烈买入评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “中等买入”，平均目标股价为 173.00 美元。</p>
</div><p><strong>Read Our Latest Research Report on JNJ</strong></p>
<div class="lb-trans"><p>阅读我们关于 JNJ 的最新研究报告</p>
</div><h2>Johnson &amp; Johnson Company Profile (Free Report)</h2>
<div class="lb-trans"><h2>强生（Johnson &amp; Johnson）公司简介（免费报告）</h2>
</div><p>Johnson &amp; Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.</p>
<div class="lb-trans"><p>强生及其子公司在全球范围内从事医疗保健领域的各种产品的研究、开发、制造和销售。该公司的创新药物部门提供各种治疗领域的产品，包括免疫学，如类风湿性关节炎、银屑病性关节炎、炎症性肠病和牛皮癣；传染病，包括艾滋病；神经科学，包括情绪障碍、神经退行性疾病和精神分裂症；肿瘤学，如前列腺癌、血液恶性肿瘤、肺癌和膀胱癌；心血管和代谢，包括血栓形成、糖尿病和黄斑变性；以及肺动脉高压，通过零售商、批发商、分销商、医院和医疗专业人士供处方使用。</p>
</div><h2>Read More</h2>
<ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>What does consumer price index measure?</li>
<li>3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In</li>
<li>How is Compound Interest Calculated?</li>
<li>Skechers Stock Shows Strength Among Consumer Discretionary Sector</li>
<li>What is an Earnings Surprise?</li>
<li>Tech Stocks Tumble, These Stocks Present Buying Opportunity</li>
</ul>
<div class="lb-trans"><h2>阅读更多</h2>
<ul>
<li>五只我们喜欢的股票，胜过强生</li>
<li>消费者价格指数衡量什么？</li>
<li>3M 惊喜和反弹加速：现在入场不算晚</li>
<li>复利利息如何计算？</li>
<li>斯凯奇股票在消费者自由选择行业表现强劲</li>
<li>什么是盈利惊喜？</li>
<li>科技股下跌，这些股票提供购买机会</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队审核。请将有关本故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ Next opportunity for crypto millions (From Crypto 101 Media)(Ad)</p>
<div class="lb-trans"><p>→ 下一个加密百万机会（来自 Crypto 101 Media）(广告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04Nzk0" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8794&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Johnson &amp; Johnson right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资$1,000 美元购买强生股票？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑购买强生股票之前，您需要听到这个消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已确定了五只顶级分析师悄悄告诉客户现在购买的股票，而强生股票不在名单上。</p>
</div><p>While Johnson &amp; Johnson currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管强生目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Capital International Inc. CA 出售了 137,587 股强生公司（NYSE:JNJ）的股票